Clinical Trial Update: Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy [Phase 2, Phase 3]

View source ↗

Summary

This update summarizes a Phase 2/Phase 3 study of StemEx for high-risk hematologic malignancies after myeloablative therapy, focusing on efficacy and safety. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• Hodgkin Lymphoma
• Myelodysplastic Syndromes
• Non-hodgkin Lymphoma

Drugs mentioned

• StemEx

Snippet

Sponsor: Gamida Cell -Teva Joint Venture Ltd. | Conditions: Hematologic Malignancies, Acute Myeloid Leukemia | Phase 2, Phase 3 | Status: COMPLETED